PMID- 25500766
OWN - NLM
STAT- MEDLINE
DCOM- 20160401
LR  - 20190828
IS  - 1860-2002 (Electronic)
IS  - 1536-1632 (Print)
IS  - 1536-1632 (Linking)
VI  - 17
IP  - 4
DP  - 2015 Aug
TI  - Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of 
      B cell NHL Imaging using Positron Emission Tomography.
PG  - 539-47
LID - 10.1007/s11307-014-0810-8 [doi]
AB  - PURPOSE: We evaluated the dosimetry of [(89)Zr]rituximab, an anti-CD20 immunoPET 
      tracer to image B cell non-Hodgkin's lymphoma (NHL) using a humanized transgenic 
      mouse model that expresses human CD20 transgenic mice (huCD20TM). PROCEDURES: 
      Rituximab was conjugated to desferrioxamine (Df) for radiolabeling of 
      Zirconium-89. [(89)Zr]rituximab (2.8 +/- 0.2 MBq) was tail vein-injected into 
      huCD20T mice. Positron emission tomography (PET)/CT imaging was performed on the 
      two groups of mice (blocking = 2 mg/kg pre-dose of rituximab and non-blocking; 
      n = 5) at eight time points (1, 4, 24, 48, 72, 96, 120, and 168 h) post 
      injection. RESULTS: The novel [(89)Zr]rituximab PET tracer had good 
      immunoreactivity, was stable in human serum, and was able to specifically target 
      human CD20 in mice. The human equivalents of highest dose (mean +/- SD) organs with 
      and without pre-dose are liver (345 +/- 284 muSv/MBq) and spleen (1165 +/- 149 
      muSv/MBq), respectively. CONCLUSIONS: Dosimetry of the human patient whole-body 
      dose was found to be 145 MBq per annum, and the patient dose-limiting organ will 
      be the liver (with rituximab pre-dose blocking) and spleen for non-blocking. The 
      [(89)Zr]rituximab (t(1/2) = 78.4 h) imaging of B cell NHL patients could permit the 
      observation of targeting lesions in NHL patients over an extended period due to 
      longer half-life as compared to the [(64)Cu] rituximab (t(1/2) = 12.7 h).
FAU - Natarajan, Arutselvan
AU  - Natarajan A
AD  - Department of Radiology, Molecular Imaging Program at Stanford (MIPS), James H. 
      Clark Center, 318 Campus Drive, E153, Stanford, CA, 94305, USA.
FAU - Gambhir, Sanjiv Sam
AU  - Gambhir SS
LA  - eng
GR  - P30 CA124435/CA/NCI NIH HHS/United States
GR  - P50 CA114747/CA/NCI NIH HHS/United States
GR  - P50CA114747/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Mol Imaging Biol
JT  - Molecular imaging and biology
JID - 101125610
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Radioisotopes)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - C6V6S92N3C (Zirconium)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - Lymphoma, B-Cell/*diagnostic imaging/*drug therapy/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Models, Biological
MH  - Phantoms, Imaging
MH  - Positron-Emission Tomography/*methods
MH  - Radioisotopes/*analysis/pharmacokinetics/therapeutic use
MH  - Radiometry
MH  - Rituximab/*therapeutic use
MH  - Zirconium/*analysis/pharmacokinetics/therapeutic use
PMC - PMC4465424
MID - NIHMS664104
COIS- Conflicts of Interest. The authors state they have no conflicts of interest
EDAT- 2014/12/17 06:00
MHDA- 2016/04/02 06:00
PMCR- 2016/08/01
CRDT- 2014/12/16 06:00
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/04/02 06:00 [medline]
PHST- 2016/08/01 00:00 [pmc-release]
AID - 10.1007/s11307-014-0810-8 [doi]
PST - ppublish
SO  - Mol Imaging Biol. 2015 Aug;17(4):539-47. doi: 10.1007/s11307-014-0810-8.